Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

35.72 -1.90 (-5.06%)
Streaming Delayed Price Updated: 12:37 PM EDT, May 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
31 32 Next >
3 Stocks With Huge Catalysts on the Way
Big news could mean big boosts for these stocks. 
Via The Motley Fool
2 Growth Stocks That Could Keep Growing for Decades
These businesses will likely only get larger in the future. 
Via The Motley Fool
Better Big Biotech Buy: Biogen vs. Vertex
One is slightly cheaper than the other. 
Via The Motley Fool
The Top 3 Biotech Stocks to Watch in 2023
Investors would be wise to keep an eye on the biotech boom, and these top biotech stocks to watch as we get deeper into 2023. 
Via InvestorPlace
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... 
Via Benzinga
Why CRISPR Therapeutics Stock Is Marching Higher Today
This gene-editing stock has been heating up over the past week. 
Via The Motley Fool
What 14 Analyst Ratings Have To Say About CRISPR Therapeutics
Via Benzinga
Is CRISPR Therapeutics Stock a Buy Now?
The biotech could soon be a commercial-stage company. 
Via The Motley Fool
CRISPR Therapeutics Is an Interesting 'Gene Editing Play for 2023' With Significant Upside, Says Analyst
Via Benzinga
3 High-Growth Biotech Stocks Poised for Success in 2023
If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity 
Via InvestorPlace
The Top Healthcare Stocks to Buy With $100
A small investment now may bring big results over time. 
Via The Motley Fool
Why Shares of Editas Medicine Rose Monday
The company is benefiting from positive news affecting other gene-editing stocks. 
Via The Motley Fool
Better Growth Stock: Axsome vs. CRISPR Therapeutics
These companies are both in the early days of their growth stories. 
Via The Motley Fool
Cathie Wood Just Bought More CRISPR Therapeutics (CRSP) Stock
Shares of CRSP stock are moving higher following an initiation of coverage by Cantor Fitzgerald and continued buys from Cathie Wood. 
Via InvestorPlace
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks. 
Via InvestorPlace
Why Shares of CRISPR Therapeutics Jumped Thursday
An independent drug-pricing group said that a $1.9 million cost for the company's exa-cel therapy would be cost-effective. 
Via The Motley Fool
Where Will CRISPR Therapeutics Be in 5 Years?
Could CRISPR Therapeutics be the next big healthcare stock? 
Via The Motley Fool
CRISPR Stock: Bull vs. Bear
CRISPR's first approved product may be right around the corner. 
Via The Motley Fool
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
Via Benzinga
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
2 Nasdaq Growth Stocks That Are Screaming Buys in April
Massive drivers of fresh earnings are drawing closer, and risks are declining. 
Via The Motley Fool
These Up-and-Coming Stocks Are Screaming Buys Right Now
Both companies could deliver revenue and share price growth over the long term. 
Via The Motley Fool
Could This Move Make Vertex's Next Blockbuster Even Bigger?
Vertex is showing it can branch out beyond its cystic fibrosis specialty. 
Via The Motley Fool
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.  
Via Benzinga
5 S&P 500 Stocks Showing Strength As Recession Fears Rise
Medical stocks are holding up amid economic and market uncertainty. 
Via Investor's Business Daily
What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio
Both biotechs are aiming for the same markets, but they are not equally risky. 
Via The Motley Fool
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
Neither stock is a good choice for those who can't handle a lot of risk. 
Via The Motley Fool
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
Via Benzinga
2 Under-the-Radar Biotech Stocks to Buy in 2023
Both companies have game-changing product portfolios that should result in stock price growth. 
Via The Motley Fool
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.